Literature DB >> 21455230

Fresh from the pipeline. Ticagrelor.

Kurt Huber1, Bashar Hamad, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21455230     DOI： 10.1038/nrd3418

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  14 in total

1.  Genetic variability in response to clopidogrel therapy: clinical implications.

Authors:  Kurt Huber
Journal:  Eur Heart J       Date:  2010-09-16       Impact factor: 29.983

2.  Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

Authors:  Christopher P Cannon; Robert A Harrington; Stefan James; Diego Ardissino; Richard C Becker; Håkan Emanuelsson; Steen Husted; Hugo Katus; Matyas Keltai; Nardev S Khurmi; Frederic Kontny; Basil S Lewis; Philippe Gabriel Steg; Robert F Storey; Daniel Wojdyla; Lars Wallentin
Journal:  Lancet       Date:  2010-01-13       Impact factor: 79.321

Review 3.  Antiplatelet therapies for the treatment of cardiovascular disease.

Authors:  Alan D Michelson
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

4.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

Authors:  Claes Held; Nils Asenblad; Jean Pierre Bassand; Richard C Becker; Christopher P Cannon; Marc J Claeys; Robert A Harrington; Jay Horrow; Steen Husted; Stefan K James; Kenneth W Mahaffey; José C Nicolau; Benjamin M Scirica; Robert F Storey; Marius Vintila; Joseph Ycas; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2010-12-30       Impact factor: 24.094

5.  Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Stefan James; Andrzej Budaj; Philip Aylward; Kristen K Buck; Christopher P Cannon; Jan H Cornel; Robert A Harrington; Jay Horrow; Hugo Katus; Matyas Keltai; Basil S Lewis; Keyur Parikh; Robert F Storey; Karolina Szummer; Daniel Wojdyla; Lars Wallentin
Journal:  Circulation       Date:  2010-08-30       Impact factor: 29.690

6.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Authors:  Lars Wallentin; Stefan James; Robert F Storey; Martin Armstrong; Bryan J Barratt; Jay Horrow; Steen Husted; Hugo Katus; P Gabriel Steg; Svati H Shah; Richard C Becker
Journal:  Lancet       Date:  2010-10-16       Impact factor: 79.321

7.  From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.

Authors:  Brian Springthorpe; Andrew Bailey; Patrick Barton; Timothy N Birkinshaw; Roger V Bonnert; Roger C Brown; David Chapman; John Dixon; Simon D Guile; Robert G Humphries; Simon F Hunt; Francis Ince; Anthony H Ingall; Ian P Kirk; Paul D Leeson; Paul Leff; Richard J Lewis; Barrie P Martin; Dermot F McGinnity; Michael P Mortimore; Stuart W Paine; Garry Pairaudeau; Anil Patel; Aaron J Rigby; Robert J Riley; Barry J Teobald; Wendy Tomlinson; Peter J H Webborn; Paul A Willis
Journal:  Bioorg Med Chem Lett       Date:  2007-08-19       Impact factor: 2.823

8.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

9.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Udaya S Tantry; Tania Gesheff; Cheryl Wei; Renli Teng; Mark J Antonino; Shankar B Patil; Arun Karunakaran; Dean J Kereiakes; Cordel Parris; Drew Purdy; Vance Wilson; Gary S Ledley; Robert F Storey
Journal:  Circulation       Date:  2009-11-18       Impact factor: 29.690

10.  Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Stefan James; Dominick J Angiolillo; Jan H Cornel; David Erlinge; Steen Husted; Frederic Kontny; Juan Maya; Josë C Nicolau; Jindrich Spinar; Robert F Storey; Susanna R Stevens; Lars Wallentin
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983
View more
  5 in total

1.  Kinetic Resolution of Cyclic Secondary Azides, Using an Enantioselective Copper-Catalyzed Azide-Alkyne Cycloaddition.

Authors:  Juliana R Alexander; Amy A Ott; En-Chih Liu; Joseph J Topczewski
Journal:  Org Lett       Date:  2019-05-22       Impact factor: 6.005

Review 2.  Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.

Authors:  S Farhan; I Tentzeris; M K Freynhofer; B Vogel; K Huber
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

Review 3.  The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).

Authors:  Mohammed Ahmed Akkaif; Nur Aizati Athirah Daud; Abubakar Sha'aban; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Dzul Azri Mohamed Noor; Baharudin Ibrahim
Journal:  Molecules       Date:  2021-04-01       Impact factor: 4.411

Review 4.  A review of the effects of ticagrelor on adenosine concentration and its clinical significance.

Authors:  Mohammed Ahmed Akkaif; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Nur Aizati Athirah Daud; Abubakar Sha'aban; Baharudin Ibrahim
Journal:  Pharmacol Rep       Date:  2021-07-20       Impact factor: 3.024

5.  An efficient and safe process for the preparation of ticagrelor, a platelet aggregation inhibitor via resin-NO2 catalyzed formation of triazole ring.

Authors:  Gorakshanath B Shinde; Pravin K Mahale; Santhosh A Padaki; Navnath C Niphade; Raghunath B Toche; Vijayavitthal T Mathad
Journal:  Springerplus       Date:  2015-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.